Jingjing Shi1, Zhichao Xue2,3, Kel Vin Tan1, Hui Yuan1,4, Anna Chi Man Tsang2,5, Sai Wah Tsao2, Pek-Lan Khong6,7. 1. Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 2. School of Biomedical Sciences, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. 3. Center for Advanced Measurement Science, National Institute of Metrology, Beijing, China. 4. Department of Nuclear Medicine, Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, Guangzhou, Guangdong, China. 5. Department of Anatomical and Cellular Pathology, The Chinese University of Hong Kong, Hong Kong SAR, China. 6. Department of Diagnostic Radiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China. dnrkpl@nus.edu.sg. 7. Clinical Imaging Research Centre, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. dnrkpl@nus.edu.sg.
Abstract
PURPOSE: We longitudinally evaluated the tumour growth and metabolic activity of three nasopharyngeal carcinoma (NPC) cell line models (C666-1, C17 and NPC43) and two xenograft models (Xeno76 and Xeno23) using a micropositron emission tomography and magnetic resonance (microPET/MR). With a better understanding of the interplay between tumour growth and metabolic characteristics of these NPC models, we aim to provide insights for the selection of appropriate NPC cell line/xenograft models to assist novel drug discovery and evaluation. METHODS: Mice were imaged by 18F-deoxyglucose ([18F]FDG) microPET/MR twice a week for consecutive 3-7 weeks. [18F]FDG uptake was quantified by standardized uptake value (SUV) and presented as SUVmean tumour-to-liver ratio (SUVRmean). Longitudinal tumour growth patterns and metabolic patterns were recorded. SUVRmean and histological characteristics were compared across the five NPC models. Cisplatin was administrated to one selected optimal tumour model, C17, to evaluate our imaging platform. RESULTS: We found variable tumour growth and metabolic patterns across different NPC tumour types. C17 has an optimal growth rate and higher tumour metabolic activity compared with C666-1. C666-1 has a fast growth rate but is low in SUVRmean at endpoint due to necrosis as confirmed by H&E. NPC43 and Xeno76 have relatively slow growth rates and are low in SUVRmean, due to severe necrosis. Xeno23 has the slowest growth rate, and a relative high SUVRmean. Cisplatin showed the expected therapeutic effect in the C17 model in marked reduction of tumour size and metabolism. CONCLUSION: Our study establishes an imaging platform that characterizes the growth and metabolic patterns of different NPC models, and the platform is well able to demonstrate drug treatment outcome supporting its use in novel drug discovery and evaluation for NPC.
PURPOSE: We longitudinally evaluated the tumour growth and metabolic activity of three nasopharyngeal carcinoma (NPC) cell line models (C666-1, C17 and NPC43) and two xenograft models (Xeno76 and Xeno23) using a micropositron emission tomography and magnetic resonance (microPET/MR). With a better understanding of the interplay between tumour growth and metabolic characteristics of these NPC models, we aim to provide insights for the selection of appropriate NPC cell line/xenograft models to assist novel drug discovery and evaluation. METHODS: Mice were imaged by 18F-deoxyglucose ([18F]FDG) microPET/MR twice a week for consecutive 3-7 weeks. [18F]FDG uptake was quantified by standardized uptake value (SUV) and presented as SUVmean tumour-to-liver ratio (SUVRmean). Longitudinal tumour growth patterns and metabolic patterns were recorded. SUVRmean and histological characteristics were compared across the five NPC models. Cisplatin was administrated to one selected optimal tumour model, C17, to evaluate our imaging platform. RESULTS: We found variable tumour growth and metabolic patterns across different NPC tumour types. C17 has an optimal growth rate and higher tumour metabolic activity compared with C666-1. C666-1 has a fast growth rate but is low in SUVRmean at endpoint due to necrosis as confirmed by H&E. NPC43 and Xeno76 have relatively slow growth rates and are low in SUVRmean, due to severe necrosis. Xeno23 has the slowest growth rate, and a relative high SUVRmean. Cisplatin showed the expected therapeutic effect in the C17 model in marked reduction of tumour size and metabolism. CONCLUSION: Our study establishes an imaging platform that characterizes the growth and metabolic patterns of different NPC models, and the platform is well able to demonstrate drug treatment outcome supporting its use in novel drug discovery and evaluation for NPC.
Authors: Anne W M Lee; Wai Tong Ng; Jimmy Y W Chan; June Corry; Antti Mäkitie; William M Mendenhall; Alessandra Rinaldo; Juan P Rodrigo; Nabil F Saba; Primož Strojan; Carlos Suárez; Jan B Vermorken; Sue S Yom; Alfio Ferlito Journal: Cancer Treat Rev Date: 2019-08-21 Impact factor: 12.111
Authors: P Busson; G Ganem; P Flores; F Mugneret; B Clausse; B Caillou; K Braham; H Wakasugi; M Lipinski; T Tursz Journal: Int J Cancer Date: 1988-10-15 Impact factor: 7.396
Authors: Bingsheng Huang; Ching-Yee Oliver Wong; Vincent Lai; Dora Lai-Wan Kwong; Pek-Lan Khong Journal: Biomed Res Int Date: 2015-04-30 Impact factor: 3.411
Authors: Marion Chomet; Maxime Schreurs; Ricardo Vos; Mariska Verlaan; Esther J Kooijman; Alex J Poot; Ronald Boellaard; Albert D Windhorst; Guus Ams van Dongen; Danielle J Vugts; Marc C Huisman; Wissam Beaino Journal: EJNMMI Res Date: 2021-06-12 Impact factor: 3.138
Authors: Simon I Okekpa; Rabiatul Basria S M N Mydin; Ernest Mangantig; Nor Syaffaf Amaliana Azmi; Siti Nur Syahirah Zahari; Gurjeet Kaur; Yusri Musa Journal: Asian Pac J Cancer Prev Date: 2019-11-01